Skip to main content

Armina Kazi

Associate Professor
Armina Kazi

Associate ProfessorArmina Kazi

Phone: 410-617-2139
Fax: 410-617-5682


Donnelly Science 376
Department of Biology
Loyola University Maryland
4501 North Charles Street
Baltimore, MD 21210-2699


I am currently doing breast cancer research whose overall goal is to understand the mechanisms involved in drug resistance in breast cancer and developing novel therapies that either prevent resistance from occurring or treat the resistant cancer. Within this goal, I am 1) studying factors that may be involved in drug resistant cancer and could be used as potential biomarkers for patient screening and as potential therapeutic targets; 2) studying association between drug resistance and cancer stem cells; and 3) studying the potential of using microRNAs as diagnostic tools for predicting drug resistance in cancer patients.


  • Curley MD, Sabnis GJ, Wille L, Adiwijaya BS, Garcia G, Moyo V, Kazi AA, Brodie A, MacBeath G. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model. Mol Cancer Ther. 2015 Nov;14(11):2642-52
  • Schech A, Kazi A, Yu S, Shah P, Sabnis G. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. Mol Cancer Ther. 2015 Aug;14(8):1848-57
  • Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2015 Aug;152(3):499-508
  • Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Res. 2014 Jan 29;16(1):R15.
  • Schech AJ, Kazi AA, Gilani RA, Brodie AH. Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Mol Cancer Ther. 2013 Jul;12(7):1356-66.
  • Sabnis GJ, Kazi A, Golubeva O, Shah P, Brodie A. Effect of Selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Res Treat. 2013 Apr;138(3):699-708.
  • Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol Cancer Ther. 2013 Dec;12(12):2804-16.
  • Gilani RA, Kazi AA*, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2012 Oct;135(3):681-92. *co-first author

Area of Specialization

  • Cancer Biology and Drug Resistance